Quarterly Activities/Appendix 4C Cash Flow Report

• Revenue for Q4 FY26: $2.3 million, FY26 total: $5.3 million (unaudited)
• Cash receipts for Q4 FY26: $3.8 million
• Cash on hand at 30 June 2026: $3.7 million
• Pharmacies in Australia selling Atomo HIV Self-Test increased by 33% during the quarter
• Successful completion of Pascal orders for two new OEM customers

Atomo Diagnostics Ltd released its Q4 FY26 quarterly report, highlighting significant financial and operational achievements. The company reported a 40% increase in revenue for the financial year, reaching $5.3 million. The fourth quarter alone saw revenue of $2.3 million. Cash receipts for Q4 FY26 totaled $3.8 million, bringing the year-to-date total to $5.3 million. Atomo remains debt-free, with cash on hand at $3.7 million as of June 30, 2026. The company also experienced a 33% increase in pharmacies in Australia selling the Atomo HIV Self-Test, with further growth anticipated. Additionally, Atomo successfully completed Pascal orders for two new OEM customers, supporting long-term supply agreements expected in Q1 FY27.

FY26 total revenue: $5.3 million, Q4 FY26 revenue: $2.3 million, Cash on hand: $3.7 million

Atomo Diagnostics Ltd anticipates continued growth in its HIV Self-Test sales and expansion of its product pipeline, including the development of a liver function test. The company is also progressing with new OEM customer agreements and product development for the upcoming financial year.